Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.
Pairing a new drug with CAR-T cell therapy may prevent the immune cells from tiring out, potentially strengthening cancer-fighting durability.
CAR T cell exhaustion limits durable responses in many hematologic malignancies. This preclinical Leukemia publication demonstrates that combining the PI3Kδ inhibitor linperlisib with MUC1-Tn CAR T cells prevents exhaustion by targeting the EGR1/DUSP2 signaling axis, offering a pharmacologic strategy to improve CAR T durability.
What the study was
- Study design
- preclinical
- Population
- Preclinical leukemia mouse models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
Standard: CAR T cell exhaustion is a central translational challenge in hematology; mechanistic insight into EGR1/DUSP2 axis is novel; PI3K inhibitor + CAR-T combination is clinically tractable; preclinical animal study — score capped per non-human conservative rule; Leukemia journal adds credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.